Omeros shares rise 34% as promising drug for eye surgeries achieves PhIII endpoint
This article was originally published in Scrip
Executive Summary
Omeros saw its shares gain $2.58 (34%), to $10.22 on 13 March after it claimed that its investigational combination drug for use in eye surgeries, OMS302, achieved it primary endpoint, which was maintaining pupil dilation (mydriasis) in intraocular lens replacement surgeries, in a US Phase III trial. The combination drug also resulted in a reduction of postoperative pain (secondary endpoint).